Merck to buy hepatitis C treatment maker Idenix Pharma for $3.85 billion in cash
WHITEHOUSE STATION, N.J. – Merck will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid worth more than triple the per-share price of the hepatitis C drug developer.
Merck & Co. says the Cambridge, Massachusetts, company has built a promising portfolio of hepatitis C treatments, including three in clinical testing
Merck will spend $24.50 per share in cash for each share, which closed at $7.23 Friday. Shares of Idenix Pharmaceuticals Inc. soared almost 240 per cent in premarket trading Monday. The boards of both companies have approved the deal.
Drugmakers are racing to develop new, potentially lucrative treatments for the blood-borne disease, which causes liver damage. The pill Sovaldi racked up more than $2 billion in sales for Gilead Sciences in its first full quarter.
Merck is based in Whitehouse Station, New Jersey.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
